Ibudilast: Completed Phase II enrollment

MediciNova said investigators completed enrollment of 250 patients in the double-blind, placebo-controlled, U.S. Phase II SPRINT-MS trial evaluating up to 50 mg ibudilast twice daily for 96 weeks. Med...